Non-alcoholic fatty liver disease
Conditions
Interventions
The research dietitian instructed all subjects to reduce their caloric intake by 300 kcal per day. The subjects were randomly assigned to receive one of the regimens
in Group A, the patients will receive Ezetimibe at a dose of 10mg per day for 6 months.
The research dietitian instructed all subjects to reduce their caloric intake by 300 kcal per day. The subjects
in Group B, the patients will receive no drug for 6 months.
Sponsors
Osaka City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. absence of clinically significant alcohol consumption (20g/day) 2. no other identifiable causes of liver diseases (infection with hepatitis B virus, hepatitis C virus, autoimmune liver diseases, and so on) 3. diagnosed as fatty liver by abdominal ultrasonography or CT 4. 180>LDL-C>140mg/dL
Exclusion criteria
Exclusion criteria: 1. past history of hypersensitivity to Ezetimibe 2. clinical sighs of severe liver injury such as acute hepatitis, acute exacerbation of chronic hepatitis, cirrhosis in Child B or C, hepatocellular carcinoma, and jaundice in combination with Statin. 3. women who are or possibly pregnant 4. past history of atherosclerotic disease(myocardial infarction , angina pectoris, cerebral stroke, and so on). 5. secondry hyperlipidemia or drug induced hyperlipidemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes of AST, ALT, Total cholesterol, and LDL-cholesterol at month 6 after the start of therapy | — |
Countries
Japan
Contacts
Public ContactHideki Fujii
Osaka City University Graduate School of Medicine Department of Hepatology
Outcome results
None listed